Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 23, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided background on a study presented at CTAD 2022 assessing the efficacy of prominent, up-and-coming anti-amyloid therapies. [WATCH TIME: 7 minutes]
In episode 10 of the NeurologyLive® series, "Challenges and Solutions in the Management of Multiple Sclerosis," an expert panel consisting of Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, considers patients with multiple sclerosis who may need to discontinue treatment during pregnancy.
In the latest edition of our in-depth Q&A series, the professor of clinical geriatric epidemiology at Karolinska Institutet provided perspective on the FINGERS trial, the first study to show it is possible to prevent cognitive decline using a multidomain lifestyle intervention.
Throughout the course of the year, the NeurologyLive® team and a number of clinician and physician partners put together feature-length, in-depth articles that encapsulate the topics and themes that have driven the conversations in the field of neurology in 2022. As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2022.
Chaired by Robert Bermel, MD, of Cleveland Clinic, the presentations also feature Jeffrey Cohen, MD; Amy Kunchock, MBBS, MMed; and Brandon Moss, MD. [WATCH TIME: 1 hour, 30 minutes]